🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› USA
Clinical trial register · United States · industry-sponsored

Industry-sponsored studies with a US investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9112 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:16 UTC
9112
Studies in scope
industry-sponsored, all four open statuses
4950
Recruiting now
open to new participants
2202
Lead sponsors
across recruiting studies
Top states
California 5295 Florida 4397 Illinois 2479 Georgia 2346 Arizona 2231
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca299 Novartis Pharmaceuticals202 Eli Lilly and Company190 Merck Sharp & Dohme LLC183 AbbVie172
State
California5295 Florida4397 Illinois2479 Georgia2346 Arizona2231
All 51 states
Target enrolment
to
9112 of 9112 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945Breast Cancer
Daiichi Sankyo
Phase 3
250
Florida, Massachusetts, New Jersey
2023-12-30
Recruiting
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb
Phase 1/2
460
Arizona, California, Florida, Massachusetts, Minnesota, Nebraska, New York, Rhode Island
2023-12-29
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
255
Alabama, California, Florida, Georgia, Illinois, New York, Texas, Virginia
2023-12-29
Active, closed
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
NCT06096337Persistent Atrial Fibrillation
Boston Scientific Corporation
Not applicable
484
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2023-12-28
Recruiting
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT05997017Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor
Aadi Bioscience, Inc.
Phase 2
29
Arkansas, Florida, Nevada, New York, North Carolina, Oklahoma, Rhode Island, Texas
2023-12-28
Recruiting
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
NCT06234397Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1
245
Florida, Michigan, Ohio, Texas
2023-12-28
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals
Phase 3
580
California, Florida, Indiana, Mississippi, New Hampshire, New York, Wisconsin
2023-12-28
Recruiting
Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
NCT05905328Cytokine Release Syndrome
CytoAgents, Inc.
Phase 1/2
54
California, Georgia, Massachusetts, North Carolina, Pennsylvania, Washington
2023-12-28
Recruiting
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240Pulmonary Hypertension, Interstitial Lung Disease
Liquidia Technologies, Inc.
Observational
80
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kentucky, Massachusetts
2023-12-28
Recruiting
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
NCT06247085Homocystinuria
Travere Therapeutics, Inc.
Phase 3
70
Arizona, Connecticut, Georgia, Illinois, Maine, Maryland, New York, North Carolina
2023-12-28
Recruiting
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
NCT06223880Major Depressive Disorder
Axsome Therapeutics, Inc.
Phase 4
350
California, Florida, Georgia, Illinois, Kansas, Louisiana, Massachusetts, Missouri
2023-12-27
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2023-12-27
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
Sanofi
Phase 3
943
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
NCT06010329Non-small Cell Lung Cancer
Teligene US
Phase 2
66
California, Florida, Georgia, Iowa, Kentucky, New York, Texas
2023-12-27
Active, closed
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Merck Sharp & Dohme LLC
Phase 2
147
Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington
2023-12-26
Active, closed
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
NCT07107373Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol-Myers Squibb
Observational
150
California
2023-12-22
Recruiting
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
NCT06132035Age-related Wet Macular Degeneration
Caregen Co. Ltd.
Phase 1
45
Connecticut, Florida, Georgia, Indiana, North Dakota, Pennsylvania
2023-12-22
Recruiting
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT06056830Prostate Cancer, Prostatic Neoplasms
Clarity Pharmaceuticals Ltd
Phase 3
383
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Kansas
2023-12-21
Active, closed
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
NCT06140836Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 3
190
Iowa, Massachusetts, New York, Washington
2023-12-21
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,264
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-21
Recruiting
A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study
NCT07045103Lung Biopsy
Invenio Imaging Inc.
Observational
900
California, Florida, Michigan, New York, North Carolina, Texas
2023-12-21
Recruiting
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
NCT05280314Melanoma, Squamous Cell Carcinoma of Head and Neck
IO Biotech
Phase 2
60
Connecticut, Massachusetts, Virginia
2023-12-21
Active, closed
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc.
Phase 2
45
Colorado, Minnesota, Ohio, Pennsylvania, South Carolina, Tennessee
2023-12-20
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
Janssen Research & Development, LLC
Phase 1
300
California, Colorado, Florida, Georgia, Michigan, New Jersey, New York, North Carolina
2023-12-20
Recruiting
A Study of LM-24C5 For Advanced Solid Tumors
NCT06187402Advanced Solid Tumor
LaNova Medicines Limited
Phase 1/2
49
California, Florida, Indiana, Ohio, Texas, Virginia
2023-12-20
Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT06154252Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Cabaletta Bio
Phase 2/3
74
California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-12-20
Active, closed
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.
Phase 3
200
California, Florida, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2023-12-20
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566CLL/SLL
Ascentage Pharma Group Inc.
Phase 3
400
Arizona, California, Florida, Illinois, Massachusetts, Michigan, North Carolina, Texas
2023-12-20
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2023-12-20
Recruiting
Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment
NCT06085183Ureter Injury
Prove pharm
Phase 4
48
New York
2023-12-20
Recruiting
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Phase 3
120
California, Colorado, Florida, Illinois, Indiana, Kentucky, Maryland, Massachusetts
2023-12-20
Recruiting
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
NCT06118086Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
Remix Therapeutics
Phase 1/2
125
California, Florida, Massachusetts, Michigan, New York, Tennessee, Texas
2023-12-20
Recruiting
LIMBER UniLeg: Rapid, On-demand, and Scaled-up Manufacturing of Customized Transtibial Prosthetic Legs for Amputees
NCT06648798Amputation of Lower Limb, Prosthesis, Non-inferiority Trial of Prothesis
LIMBER Prosthetics & Orthotics Inc
Not applicable
30
California
2023-12-20
Recruiting
Danon Disease Natural History Study
NCT06214507Danon Disease
Rocket Pharmaceuticals Inc.
Observational
60
Arizona, California, Colorado, Florida, Michigan, Missouri, New York, Texas
2023-12-20
Recruiting
Contraceptive Efficacy Study of Ovaprene
NCT06127199Contraception
Daré Bioscience, Inc.
Not applicable
656
Arizona, California, Colorado, Georgia, Hawaii, Louisiana, Maryland, Massachusetts
2023-12-19
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
AbbVie
Phase 3
614
Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2023-12-19
Recruiting
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
NCT05828511Multiple Myeloma
Regeneron Pharmaceuticals
Phase 1/2
149
California, Colorado, Kentucky, Michigan, New Jersey, New York, North Carolina, Texas
2023-12-19
Recruiting
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
NCT04234048T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified
SciTech Development, Inc.
Phase 1
46
Arizona, California, Colorado, Illinois, Michigan, New York, Pennsylvania, Texas
2023-12-18
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Taiho Oncology, Inc.
Phase 3
285
Nevada, Ohio, Texas
2023-12-18
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-18
Active, closed
Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population
NCT07382076Activated Clotting Time
Abbott Point of Care
Observational
500
Arizona, California, District of Columbia, Kentucky, Maryland, Minnesota, Missouri, New York
2023-12-15
Recruiting
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
NCT05789758Muscular Atrophy, Spinal
Biogen
Observational
20
California, Massachusetts, New York
2023-12-15
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
614
Arizona, California, Colorado, Florida, Georgia, Kentucky, Maine, Massachusetts
2023-12-15
Active, closed
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
CG Oncology, Inc.
Phase 3
367
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-14
Recruiting
A Study of JNJ-87890387 for Advanced Solid Tumors
NCT06178614Neoplasms, Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1
200
Michigan, Tennessee
2023-12-14
Active, closed
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
94
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, New Jersey
2023-12-14
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-12-14
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
Sanofi
Phase 3
1,655
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-13
Recruiting
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
NCT06011109Glioma, Glioblastoma Multiforme
Aveta Biomics, Inc.
Phase 1/2
30
Minnesota, Nebraska
2023-12-13
Active, closed
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT05734105GIST
Deciphera Pharmaceuticals, LLC
Phase 3
54
California, Connecticut, Florida, Maryland, Massachusetts, Minnesota, New York, Ohio
2023-12-13
Recruiting
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
NCT06185192Diabetes
Viome
Not applicable
100
Washington
2023-12-13
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Indiana
2023-12-13
Recruiting
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
NCT05761223Advanced Solid Tumor
1ST Biotherapeutics, Inc.
Phase 1/2
151
Ohio, Texas, Virginia, Washington
2023-12-13
Active, closed
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
NCT06101342Pre-Exposure Prophylaxis of HIV Infection
Gilead Sciences
Phase 2
181
California, Florida, Maryland, New Jersey, New York, Pennsylvania, Texas, West Virginia
2023-12-13
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)
Regeneron Pharmaceuticals
Phase 3
904
Arizona, California, Florida, Indiana, Kentucky, Maryland, Massachusetts, Michigan
2023-12-13
Active, closed
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
NCT05951959Mantle Cell Lymphoma (MCL)
AstraZeneca
Phase 2
108
New Jersey, New York, Ohio, Pennsylvania, Texas
2023-12-13
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intellia Therapeutics
Phase 3
1,200
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-13
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 2
226
California, Kentucky, New York, Rhode Island, Texas
2023-12-13
Recruiting
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
NCT06091254Follicular Lymphoma (FL)
Regeneron Pharmaceuticals
Phase 3
822
Arizona, California, Indiana, Massachusetts, Michigan, Mississippi, New York, North Carolina
2023-12-12
Active, closed
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
NCT07116889Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Generate Biomedicines
Phase 1
156
Florida, Minnesota, North Carolina, Texas
2023-12-12
Active, closed
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323Prurigo Nodularis
Sanofi
Observational
100
Arizona, California, Florida, Georgia, Indiana, Michigan, Missouri, Nebraska
2023-12-12
Active, closed
Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
NCT06152237Rett Syndrome
Taysha Gene Therapies, Inc.
Phase 1/2
6
Illinois, Minnesota, Missouri
2023-12-12
Recruiting
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074Advanced Solid Malignancies
Georgiamune Inc
Phase 1/2
111
California, Florida, Kentucky, New Jersey, Tennessee, Texas, Virginia
2023-12-12
Recruiting
HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors
NCT05861895Solid Tumors, Adult
HighField Biopharmaceuticals Corporation
Phase 1
84
Texas
2023-12-12
Recruiting
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
NCT06253130Advanced Solid Tumor
Eikon Therapeutics
Phase 1/2
156
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Michigan, Minnesota
2023-12-11
Active, closed
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443Metastatic Castration-resistant Prostate Cancer
OncoC4, Inc.
Phase 1/2
148
California, Colorado, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nebraska
2023-12-11
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
AbbVie
Phase 3
110
Arizona, Arkansas, California, Colorado, Florida, Indiana, Massachusetts, Minnesota
2023-12-11
Recruiting
A Long-Term Follow-Up Study of Participants Exposed to REACT
NCT05918523Diabetic Kidney Disease, Chronic Kidney Diseases
Prokidney
Observational
80
Idaho
2023-12-11
Active, closed
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)
NCT06111586Type 1 Diabetes Mellitus
Sanofi
Phase 2
197
California, Colorado, Florida, Idaho, Illinois, Massachusetts, New York, North Carolina
2023-12-11
Active, closed
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
NCT06496568PIK3CA-Mutated Cancers
Hoffmann-La Roche
Phase 1
30
Tennessee
2023-12-11
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche
Phase 3
1,050
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kentucky, Maine
2023-12-11
Active, closed
A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
NCT06149403MPS-IH (Hurler Syndrome)
Orchard Therapeutics
Phase 3
41
Minnesota
2023-12-11
Recruiting
Zenith® Fenestrated+ Clinical Study
NCT04875429Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Cook Research Incorporated
Not applicable
105
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Maryland
2023-12-08
Active, closed
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
NCT06162585Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases
Nanoscope Therapeutics Inc.
Observational
18
California, Florida, North Dakota, Texas
2023-12-08
Recruiting
Spartan Stem, World Cup and World Liner Post Market Clinical Follow-up Study
NCT06172569Hip Replacement
Signature Orthopaedics
Observational
200
Ohio
2023-12-08
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Connecticut, Florida, Georgia, Minnesota, Nebraska, New York, Oregon, South Carolina
2023-12-08
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
Novartis Pharmaceuticals
Phase 3
362
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2023-12-07
Active, closed
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
NCT06181136Mucopolysaccharidosis Type IIIA
Denali Therapeutics Inc.
Phase 1/2
20
California, Iowa, North Carolina, Texas
2023-12-07
Recruiting
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
NCT06075264Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia
Frantz Viral Therapeutics, LLC
Phase 2
27
Florida, Indiana, Ohio
2023-12-06
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2023-12-06
Active, closed
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Aura Biosciences
Phase 3
108
California, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2023-12-06
Active, closed
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153Neovascular Age-related Macular Degeneration (nAMD)
Alcon Research
Phase 1/2
139
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-12-06
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
868
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-12-06
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic
BriaCell Therapeutics Corporation
Phase 3
404
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2023-12-05
Recruiting
SportsPro: Post-Market Clinical Follow Up Study
NCT06320925Shoulder Injuries, Knee Injuries, Hip Injuries
Stryker Endoscopy
Observational
1,500
Arizona, Colorado, Texas
2023-12-05
Active, closed
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972Ulcerative Colitis
Gilead Sciences
Phase 2
176
Arizona, California, Florida, Michigan, Minnesota, Mississippi, Missouri, New York
2023-12-05
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945Multiple Myeloma
AstraZeneca
Phase 1/2
226
California, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Virginia
2023-12-05
Recruiting
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca
Phase 1/2
564
Missouri, Rhode Island, Tennessee, Texas
2023-12-05
Recruiting
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT06034002Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
290
California, Florida, Kansas, Maryland, Massachusetts, Missouri, New York, North Carolina
2023-12-04
Active, closed
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
NCT06109441Ulcerative Colitis
AltruBio Inc.
Phase 2
50
California, Colorado, Florida, Indiana, Kentucky, Louisiana, Mississippi, New York
2023-12-04
Active, closed
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740Advanced Solid Tumor, Hepatocellular Carcinoma
TORL Biotherapeutics, LLC
Phase 1
70
Arizona, California, Florida, Minnesota, Virginia
2023-12-04
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2023-12-04
Active, closed
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
NCT05867914Hypertension, Pulmonary, Lung Diseases, Interstitial
Third Pole Therapeutics, Inc.
Not applicable
5
Florida, Ohio, South Carolina
2023-12-04
Recruiting
Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy
NCT05826743Colorectal Surgery, Colorectal Cancer, Rectal/Anal, Ileostomy - Stoma
JSR Medical Co., Ltd.
Not applicable
256
New York, Pennsylvania, Texas
2023-12-04
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043Ulcerative Colitis
AnaptysBio, Inc.
Phase 2
132
Arizona, California, Florida, Georgia, Illinois, Nevada, New York, Ohio
2023-12-04
Active, closed
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
NCT05972278Lipid Metabolism
NewAmsterdam Pharma
Phase 1
22
Pennsylvania
2023-12-01
Active, closed
Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
NCT05938036Acute Respiratory Distress Syndrome (ARDS)
Aqualung Therapeutics Corp.
Phase 2
15
Arizona
2023-12-01
By invitation
Exactech Knee Systems Post Market Clinical Follow-up
NCT07107581Knee Arthroplasty, Total, Partial Knee Replacement
Exactech
Observational
1,879
Florida
2023-12-01
Recruiting
Prospective Registry to Evaluate Outcomes of NanoBone® Bone Graft in Acute Trauma
NCT06256458Fractures, Bone
Artoss Inc.
Observational
200
Wisconsin
2023-12-01
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
BeOne Medicines
Phase 1
433
Colorado, Florida, Michigan, Missouri, North Carolina, Ohio, Tennessee, Texas
2023-12-01
Rows per page Showing 5601–5700 of 9112
Previous 55 56 57 58 59 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-usa?page=57

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
→

Browse trials by condition

Advanced Solid Tumor (143) Breast Cancer (139) Obesity (123) Multiple Myeloma (109) Advanced Solid Tumors (89) Colorectal Cancer (83) Solid Tumor (81) Overweight (77) Ovarian Cancer (74) Healthy (73) Prostate Cancer (73) Heart Failure (72) Non-Small Cell Lung Cancer (70) Cancer (65) Melanoma (63)
→

Browse trials by state

California (5295) Florida (4397) Illinois (2479) Georgia (2346) Arizona (2231) New York (2126) Colorado (2066) Texas (1969) Massachusetts (1836) Michigan (1481) Alabama (1288) Connecticut (1274) Maryland (1267) Ohio (1252) Indiana (1114)
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.